In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The company’s shares opened today at $1.95. According ...

BrainStorm (BCLI) announced that the company received written notice from The Nasdaq Stock Market stating that the company has regained ...

How did Subaru move from selling only 150,000 cars yearly to over 700,000? You can brainstorm all you want in the corporate ...

Talking to someone who is not from your field of work can be beneficial in mastermind sessions, as you often gain insights ...

The lowered price target reflects these complex factors as the company moves forward with its ALS treatment research. In other recent news, BrainStorm Cell Therapeutics Inc. successfully regained ...

Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

The Homeless Coordinating Council — consisting of members from the city, Bernalillo County and the University of New Mexico — ...

In today’s digitalized, fast-paced work settings, most enterprises need collaboration software to maintain a smooth workflow.

As Donald Trump gets set to return to the White House, several big chip companies are racing to finalize deals under the 2022 ...

The trial is backed by a Special Protocol Assessment (SPA) with the FDA and has established alignment on manufacturing processes, which are crucial to the company's recovery trajectory. The analyst ...